Nang Kuang Pharmaceutical Co., Ltd. Listed by incransom Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

On February 15, 2026, the ransomware group incransom listed Nang Kuang Pharmaceutical Co., Ltd. on its leak site. The entry states that 430 gigabytes of internal files were taken from the company and describes the material as including client agreements, project documentation, and certain personal records. No independent confirmation of the volume, contents, or circumstances of any exfiltration has been made public, and the number of individuals affected remains unknown. This listing adds to the record of ransomware operations that continue to focus on organizations holding research, regulatory, and commercial information.

Breaking down the breach

The only confirmed public information is the February 15, 2026 listing itself. The group claims that files were removed during a ransomware intrusion and that the total volume reached 430 gigabytes. No date of intrusion, method of initial access, or evidence of encryption has been disclosed. The organization has not issued a statement confirming or denying the claims.

Inside incransom

Incransom operates as a ransomware group that employs double-extortion tactics, encrypting victim systems while also copying data for later publication or sale. Public reporting on the group shows repeated targeting of mid-sized companies across manufacturing, technology, and healthcare sectors. Listings on its leak site function as pressure on victims to negotiate; the accuracy of any individual claim is not independently verified unless corroborated by the affected organization or law-enforcement findings.

Who is Nang Kuang Pharmaceutical Co., Ltd.?

Nang Kuang Pharmaceutical Co., Ltd. is a Taiwan-based manufacturer of pharmaceutical products with reported annual revenue of 70 million dollars. Companies in this sector routinely maintain records of drug-development projects, clinical-study data, manufacturing agreements, and regulatory submissions. They also hold contact information and, in some cases, identity documents for employees, contractors, and research partners. A compromise of such records can affect both commercial operations and the privacy of individuals whose information appears in internal files.

The information in question

The listing describes the exfiltrated material as internal files containing client and partner details, project documentation for products such as Eroxon, Cinacalcet, Icatibant, Exparel, and bupivacaine, as well as agreements, clinical reports, lawsuit materials, and certain personal records including identity scans and email addresses. The exact scope and sensitivity of any data that may have been taken have not been confirmed by the company or by investigators.

Why it matters

Pharmaceutical records often contain information that is both commercially sensitive and subject to regulatory protections. Exposure of clinical reports or partnership agreements can create competitive or legal exposure for the organization. Where personal identifiers such as identity scans or email addresses are involved, affected individuals face the ordinary risks associated with the misuse of such data, including targeted phishing or account takeover attempts. Because the number of individuals whose information may be present is unknown, the full extent of downstream impact cannot yet be assessed.

Were you affected?

Individuals who have had professional contact with Nang Kuang Pharmaceutical Co., Ltd. or its partners have no immediate way to confirm exposure from public sources. Practical steps include monitoring email accounts and financial services for unusual activity, using unique passwords with a password manager, and enabling multi-factor authentication on important accounts. Readers can also run a free exposure scan of their email address against known breach data sets to check for prior appearances of their information.

• Review recent account activity on email and financial services
• Enable multi-factor authentication where available
• Replace reused passwords with unique, generated ones
• Watch for unsolicited messages referencing the company or its projects

AICompiled with AI assistance from public sources and published under our editorial standards.